Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Jennifer Ligibel Discusses New Data Strengthening the Link Between Obesity and Cancer

November 15, 2016
By Jennifer A. Ligibel, MD
Podcast

In this interview we discuss a recent report from the International Agency for Research on Cancer that evaluated the evidence linking obesity to cancer risk.

Oncology (Williston Park). 30(11):952,1007.

Jennifer A. Ligibel, MD

Your browser does not support the audio element.

1. The International Agency for Research on Cancer (IARC) recently published a new evaluation of the evidence linking overweight and obesity to cancer risk. Can you provide some background and explain why the IARC reviews this evidence?

Dr. Ligibel: There is growing evidence that obese individuals are at increased risk of developing and dying from malignancy. Interest has grown in studying the relationship between body weight and cancer risk, especially after the publication of a seminal study by Calle et al published in the early 2000s in the New England Journal of Medicine (NEJM) that followed a large cohort of Americans for about 20 years and demonstrated that the heaviest members of the cohort had a significantly increased risk of developing and dying from cancer as compared with normal weight individuals. Over time, the evidence linking obesity to cancer risk and cancer outcomes has grown. In 2002, the IARC initially summarized the observational data linking obesity and cancer risk and graded the strength of the evidence to determine if it was sufficient to declare a consistent relationship between obesity and cancer risk for a number of different malignancies.

2.What, if anything, makes obesity a tricky subject to examine as far as its connection with many diseases, but with cancer specifically?

Dr. Ligibel: The data that link obesity to cancer risk come from a number of different types of studies, including case-control studies in which people are evaluated after they develop malignancy and are matched with similar individuals in the community to determine whether there is an association between body weight and cancer risk, and large prospective cohort studies that look at the relationship between body weight over time and the incidence of malignancy. Since the last IARC report, we have seen stronger evidence emerge from these studies that supports the relationship between obesity and cancer risk. One of the complicated aspects of studying the relationship between obesity and disease is that we typically define obesity based on body mass index (BMI), which is a normalized measure that takes into consideration an individual’s height and weight. We recognize that people can have different body compositions at different BMIs. There are some individuals who, although they have a high BMI, may have a higher proportion of muscle or they may have less of the types of body fat that we think leads to increased cancer risk, specifically visceral adiposity or excess weight in the visceral area of the body, rather than subcutaneous fat. One of the things that makes this area difficult to study is that our common measures provide us with a relatively limited view of what is happening at an individual level from a metabolic standpoint. There may be people who are heavier, but who are also metabolically healthy, and there are individuals who are leaner with a high proportion of body fat. That is one of the shortcomings of the evidence that we have linking obesity to cancer, as well as other diseases.

3. In 2002 when the IARC evaluation was published, the group concluded that there was a link between obesity and certain cancers. Can you discuss what was found then and what the most recent review published in NEJM has updated?

Dr. Ligibel: In 2002, the IARC review evaluated the existing data evaluating the relationship between obesity and cancer risk. At that point there were already hundreds of case-control and cohort studies looking at this relationship. The 2002 IARC working group determined that there was sufficient evidence linking obesity to the risk of developing a number of malignancies, including postmenopausal breast cancer, endometrial cancer, and some gastrointestinal cancers. In 2016, when this evaluation was repeated, the number of studies had grown exponentially, almost to the point where it was very difficult to even summarize all of the data linking obesity to malignancy. The list of malignancies for which the strength of evidence in humans was felt to be significant was expanded to include a number of additional malignancies, such as multiple myeloma and pancreatic cancer. In other malignancies, such as prostate cancer, the evidence is still emerging. Finally, an inverse relationship was found between obesity and cancer in some malignancies, especially in cancers where smoking is a causative factor.

4.Based on the evidence available today, what should clinicians do to adjust their practice?

Dr. Ligibel: The data that link obesity to cancer risk are primarily observational. There are no trials, at this point, that have looked at the impact of weight loss interventions on cancer risk. There are some very interesting data emerging that demonstrate that patients with higher levels of obesity who undergo bariatric surgery have a dramatic decrease in risk for developing cancer in subsequent years. However, these data are not from randomized trials, but rather observational studies that provide some of the first proof that weight loss can be an effective way of potentially avoiding malignancy. As clinicians, recognizing the increased risk of malignancy imparted by obesity is important. When counseling an obese patient about health risks, clinicians should not only consider risk of cardiovascular disease or diabetes, but also the risk of cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.

3 Things You Should Know About Advancing mCRPC Care: Targeted Sequencing, Epigenetics, and Emerging Strategies

ONCOLOGY Staff
July 1st 2025
Article

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.


Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.

The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes

ONCOLOGY Staff
June 29th 2025
Article

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.


Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article


Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment

ONCOLOGY Staff
June 26th 2025
Article

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Related Content

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.

3 Things You Should Know About Advancing mCRPC Care: Targeted Sequencing, Epigenetics, and Emerging Strategies

ONCOLOGY Staff
July 1st 2025
Article

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.


Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.

The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes

ONCOLOGY Staff
June 29th 2025
Article

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.


Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article


Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment

ONCOLOGY Staff
June 26th 2025
Article

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.